Description
WSD-0922 is a potent, selective, orally active, and BBB penetrable EGFR/EGFRVIII inhibitor. WSD-0922 is against EGFRm+ (EGFRvIII/Del19/L858R) with an IC50 of <10 nM. WSD0922 shows good safety profile and preclinical anti-tumor efficacy.
Product information
CAS Number: 2226552-64-1
Molecular Weight: 442.43
Formula: C23H21F3N4O2
Chemical Name: 6-{[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy}-N-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine
Smiles: COC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3F)=C2C=C1O[C@@H]1CCN(C)CC1(F)F
InChiKey: RIHUDRGMCALEAK-HXUWFJFHSA-N
InChi: InChI=1S/C23H21F3N4O2/c1-4-14-6-5-7-16(21(14)24)29-22-15-10-19(18(31-3)11-17(15)27-13-28-22)32-20-8-9-30(2)12-23(20,25)26/h1,5-7,10-11,13,20H,8-9,12H2,2-3H3,(H,27,28,29)/t20-/m1/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vivo:
WSD0922 treatment results in tumor regression on cetuximab resistant PDX model of HNSCC. WSD0922 demonstrates remarkable tumor regression in 3 PDX models (platinum sensitive/insensitive/EGFRm+). WSD0922 is well tolerated in GLP tox at dose ~10x clinical equivalent dose.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.